Professor John Strang
Professor of Addictions & Head of Department
We are very proud to congratulate long-standing SSA Trustee, Professor Sir John Strang, who was named in HM Queen Elizabeth’s birthday honours list, 2016.
Professor Sir John Strang is one of only six addictions researchers outside North America identified by ISI (the Institute for Scientific Analysis) as a “Highly Cited Author” with a rate of citation in the “top one half of one percent of all publishing researchers in the last two decades”. He has published extensively in the addictions field, with more than 500 publications, and is Head of the Addictions Department. He also has extensive experience as a Lead Clinician for a wide range of treatments in community and residential settings and has been a Consultant Psychiatrist in addictions treatment for over 30 years.
Professor Strang is Head of the Addictions Department and is also Leader of the Addictions CAG (Clinical Academic Group) within King’s Health Partners, in which Addictions is one of the core areas of the Academic Health Science Centre (AHSC). This brings together university partners King’s College London (KCL) with the NHS from South London and Maudsley NHS Foundation Trust, King’s College Hospital, and Guy’s and St Thomas’s NHS Foundation Trust.
The Addictions Department itself is hugely productive. The highly influential report by RAND Europe rates Substance Abuse Research at the National Addiction Centre as leading the field in UK Universities, with our Addictions (Substance Abuse) publications leading the field at 13%, with all other institutions except two scoring under 5%.
Professor Strang has chaired and/or served on key committees or guidelines groups for the Department of Health, for NICE (the National Institute of Health and Clinical Excellence) and for the World Health Organisation (WHO). This provides opportunity to bring relevant evidence from new scientific studies and systematic reviews to the policy-making work of these committees.
Professor Strang presents on the ongoing challenges for distribution and implementation of Naloxone.
The audio attached to this presentation also includes the Q & A Session at the end of the conference.
